What is HC Wainwright's Estimate for RAPT Q2 Earnings?

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Stock analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of RAPT Therapeutics in a research report issued to clients and investors on Thursday, May 22nd. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a "Strong-Buy" rating and a $6.00 target price on the stock. The consensus estimate for RAPT Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.74) EPS.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.23.

Several other equities research analysts have also weighed in on the company. UBS Group cut their target price on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Wall Street Zen raised RAPT Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $3.00.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT traded down $0.03 during midday trading on Monday, hitting $0.94. 368,572 shares of the company's stock were exchanged, compared to its average volume of 1,284,915. RAPT Therapeutics has a twelve month low of $0.71 and a twelve month high of $4.60. The company has a market cap of $124.75 million, a PE ratio of -0.34 and a beta of -0.04. The firm's fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.14.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RAPT. JPMorgan Chase & Co. increased its position in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after buying an additional 25,130 shares during the period. SG Americas Securities LLC increased its position in RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock worth $84,000 after buying an additional 42,636 shares during the period. Medicxi Ventures Management Jersey Ltd acquired a new position in RAPT Therapeutics during the fourth quarter worth approximately $35,316,000. Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock valued at $348,000 after purchasing an additional 18,558 shares during the last quarter. Finally, Callan Family Office LLC purchased a new position in shares of RAPT Therapeutics in the 4th quarter valued at approximately $92,000. Institutional investors and hedge funds own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.